A patient with genetically confirmed myoclonus-dystonia responded to anticholinergic treatment and improved spontaneously

16Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Background The various medical treatments applied to myoclonus-dystonia patients with a mutation of the e-sarcoglycan gene (SGCE) have not been beneficial in most cases. Most patients experience progressive deterioration or static clinical courses, with only rare cases of spontaneous remission. Case Report A 19-year-old girl presented with a 14-year history of myoclonus and dystonia that severely affected her left arm, neck, and trunk. Genetic studies showed a mutation in SGCE [deletion in exon 6 (c.771_772delAT, Cys258X)]. Both myoclonus and dystonia responded to anticholinergic treatment for 7 years and improved spontaneously. Conclusions The possibility of spontaneous improvement should be kept in mind when considering the therapeutic strategy in myoclonus-dystonia patients, especially when contemplating deep-brain stimulation. © 2011 Korean Neurological Association.

Cite

CITATION STYLE

APA

Lee, J. H., Lyoo, C. H., & Lee, M. S. (2011). A patient with genetically confirmed myoclonus-dystonia responded to anticholinergic treatment and improved spontaneously. Journal of Clinical Neurology (Korea), 7(4), 231–232. https://doi.org/10.3988/jcn.2011.7.4.231

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free